Control of intracellular calcium signaling as a neuroprotective strategy

Molecules

Volumn 15, Issue 3, 2010, Pages 1168-1195

  Duncan, R Scott ^a   Goad, Daryl L ^a   Grillo, Michael A ^a   Kaja, Simon ^a   Payne, Andrew J ^a   Koulen, Peter ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Accessory proteins; Associated proteins; Ca2+; Calcium; Cytoprotection; Extracellular; G protein coupled receptors; Imaging; Intracellular; Intracellular calcium channel; Ion channel; Microscopy; Neurodegeneration; Neuroprotection; Signaling

Indexed keywords

NEUROPROTECTIVE AGENT;

ANIMAL; ARTICLE; CALCIUM SIGNALING; HUMAN; METABOLISM; MOUSE; TRANSGENIC MOUSE;

ANIMALS; CALCIUM SIGNALING; HUMANS; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS;

EID: 77950362173     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules15031168     Document Type: Article

References (238)

1. Hardingham, G. E.; Chawla, S.; Johnson, C. M. Bading, H. Distinct functions of nuclear and cytoplasmic calcium in the control of gene expression. Nature 1997, 385, 260-265. (Pubitemid 27043726)
2. Bading, H. Transcription-dependent neuronal plasticity the nuclear calcium hypothesis. Eur. J. Biochem. 2000, 267, 5280-5283.
3. West, A. E.; Chen, W. G.; Dalva, M. B.; Dolmetsch, R. E.; Kornhauser, J. M.; Shaywitz, A. J.; Takasu, M. A.; Tao, X.; M. E. Greenberg. Calcium regulation of neuronal gene expression. Proc. Natl. Acad. Sci. USA 2001, 98, 11024-11031. (Pubitemid 32928677)
4. Simkus, C. R.; Stricker, C. The contribution of intracellular calcium stores to mEPSCs recorded in layer II neurones of rat barrel cortex. J. Physiol. 2002, 545, 521-535. (Pubitemid 36004386)
5. Unni, V. K.; Zakharenko, S. S.; Zablow, L.; DeCostanzo, A. J.; Siegelbaum, S. A. Calcium release from presynaptic ryanodine-sensitive stores is required for long-term depression at hippocampal CA3-CA3 pyramidal neuron synapses. J. Neurosci. 2004, 24, 9612-9622. (Pubitemid 39441515)
6. 2+ stores. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 2005, 142, 355-361. (Pubitemid 41571328)
7. 2+ release modulates synaptic transmission in hippocampal neurons. Brain Res. Mol. Brain Res. 2005, 135, 232-248. (Pubitemid 40602415)
8. Liu, Q.; Chen, B.; Yankova, M.; Morest, D. K.; Maryon, E.; Hand, A. R.; Nonet, M. L.; Wang, Z. W. Presynaptic ryanodine receptors are required for normal quantal size at the Caenorhabditis elegans neuromuscular junction. J. Neurosci. 2005, 25, 6745-6754. (Pubitemid 41023142)
9. Suryanarayanan, A.; Slaughter, M. M. Synaptic transmission mediated by internal calcium stores in rod photoreceptors. J. Neurosci. 2006, 26, 1759-1766. (Pubitemid 43236988)
10. Mathew, S. S.; Hablitz, J. J. Calcium release via activation of presynaptic IP3 receptors contributes to kainate-induced IPSC facilitation in rat neocortex. Neuropharmacology 2008, 55, 106-116.
11. Kelliher, M.; Fastbom, J.; Cowburn, R. F.; Bonkale, W.; Ohm, T. G.; Ravid, R.; Sorrentino, V.; O'Neill, C. Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and beta-amyloid pathologies. Neuroscience 1999, 92, 499-513. (Pubitemid 29268039)
12. Bezprozvanny, I.; Hayden, M. R. Deranged neuronal calcium signaling and Huntington disease. Biochem. Biophys. Res. Commun. 2004, 322, 1310-1317. (Pubitemid 39164659)
13. 2+ signals and altered membrane excitability. J. Neurosci. 2004, 24, 508-513. (Pubitemid 38112383)
14. 2+ release in the 3xTg-AD mouse model of Alzheimer's disease. J. Neurochem. 2005, 94, 1711-1718. (Pubitemid 41324651)
15. 2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc. Natl. Acad. Sci. USA 2005, 102, 2602-2607. (Pubitemid 40279423)
16. Ferreiro, E.; Resende, R.; Costa, R.; Oliveira, C. R.; Pereira, C. M. An endoplasmic-reticulumspecific apoptotic pathway is involved in prion and amyloid-beta peptides neurotoxicity. Neurobiol. Dis. 2006, 23, 669-678. (Pubitemid 44234104)
17. 2+ content in presenilin double knock-out cells. Cell Calcium. 2006, 40, 41-51. (Pubitemid 43785820)
18. Supnet, C.; Grant, J.; Kong, H.; Westaway, D.; Mayne, M. Amyloid-beta-(1-42) increases ryanodine receptor-3 expression and function in neurons of TgCRND8 mice. J. Biol. Chem. 2006, 281, 38440-38447. (Pubitemid 46041967)
19. Stokes, C. E.; Hawthorne, J. N. Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-diseased brains. J. Neurochem. 1987, 48, 1018-1021.
20. Young, L. T.; Kish, S. J.; Li, P. P.; Warsh, J. J. Decreased brain [3H]inositol 1,4,5-trisphosphate binding in Alzheimer's disease. Neurosci. Lett. 1988, 94, 198-202.
21. Ferrari-DiLeo, G.; Flynn, D. D. Diminished muscarinic receptor-stimulated [3H]-PIP2 hydrolysis in Alzheimer's disease. Life Sci. 1993, 53, 439-444. (Pubitemid 2019042)
22. Crews, F. T.; Kurian, P.; Freund, G. Cholinergic and serotonergic stimulation of phosphoinositide hydrolysis is decreased in Alzheimer's disease. Life Sci 1994, 55, 1993-2002. (Pubitemid 24372588)
23. Garlind, A.; Cowburn, R. F.; Forsell, C.; Ravid, R.; Winblad, B.; Fowler, C. J. Diminished [3H]inositol (1, 4, 5) P3 but not [3H]inositol (1, 3, 4, 5) P4 binding in Alzheimer's disease brain. Brain Res. 1995, 681, 160-166.
24. Kurumatani, T.; Fastbom, J.; Bonkale, W. L.; Bogdanovic, N.; Winblad, B.; Ohm, T. G.; Cowburn, R. F. Loss of inositol 1,4,5-trisphosphate receptor sites and decreased PKC levels correlate with staging of Alzheimer's disease neurofibrillary pathology. Brain Res. 1998, 796, 209-221. (Pubitemid 28343250)
25. Bezprozvanny, I.; Mattson, M. P. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 2008, 31, 454-463.
26. Chan, S. L.; Mayne, M.; Holden, C. P.; Geiger, J. D.; Mattson, M. P. Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J. Biol. Chem. 2000, 275, 18195-18200. (Pubitemid 30414771)
27. Rybalchenko, V.; Hwang, S. Y.; Rybalchenko, N.; Koulen, P. The cytosolic N-terminus of presenilin-1 potentiates mouse ryanodine receptor single channel activity. Int. J. Biochem. Cell Biol. 2008, 40, 84-97. (Pubitemid 350052661)
28. Hayrapetyan, V.; Rybalchenko, V.; Rybalchenko, N.; Koulen, P. The N-terminus of presenilin-2 increases single channel activity of brain ryanodine receptors through direct protein-protein interaction. Cell Calcium 2008, 44, 507-518.
29. Stutzmann, G. E.; Smith, I.; Caccamo, A.; Oddo, S.; Parker, I.; Laferla, F. Enhanced ryanodinemediated calcium release in mutant PS1-expressing Alzheimer's mouse models. Ann. NY Acad. Sci. 2007, 1097, 265-277. (Pubitemid 47084900)
30. Lee, S. Y.; Hwang, D. Y.; Kim, Y. K.; Lee, J. W.; Shin, I. C.; Oh, K. W.; Lee, M. K.; Lim, J. S.; Yoon, D. Y.; Hwang, S. J.; Hong, J. T. PS2 mutation increases neuronal cell vulnerability to neurotoxicants through activation of caspase-3 by enhancing of ryanodine receptor-mediated calcium release. FASEB J. 2006, 20, 151-153.
31. Leissring, M. A.; Parker, I.; LaFerla, F. M. Presenilin-2 mutations modulate amplitude and kinetics of inositol 1,4,5-trisphosphate-mediated calcium signals. J. Biol. Chem. 1999, 274, 32535-32538. (Pubitemid 129535275)
32. 2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron 2008, 58, 871-883.
33. Qin, Z. H.; Gu, Z. L. Huntingtin processing in pathogenesis of Huntington disease. Acta Pharmacol. Sin. 2004, 25, 1243-1249. (Pubitemid 39361794)
34. Linseman, D. A. Targeting oxidative stress for neuroprotection. Antioxid. Redox. Signal 2009, 11, 421-424.
35. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72, 971-983. (Pubitemid 23110238)
36. Tang, T. S.; Tu, H.; Chan, E. Y.; Maximov, A.; Wang, Z.; Wellington, C. L.; Hayden, M. R.; Bezprozvanny, I. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1, 4, 5) triphosphate receptor type 1. Neuron 2003, 39, 227-239. (Pubitemid 36897546)
37. Tang, T. S.; Guo, C.; Wang, H.; Chen, X.; Bezprozvanny, I. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model. J. Neurosci. 2009, 29, 1257-1266.
38. Luthi-Carter, R.; Hanson, S. A.; Strand, A. D.; Bergstrom, D. A.; Chun, W.; Peters, N. L.; Woods, A. M.; Chan, E. Y.; Kooperberg, C.; Krainc, D.; Young, A. B.; Tapscott, S. J.; Olson, J. M. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 2002, 11, 1911-1926.
39. Vucic, S.; Kiernan, M. C. Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. Curr. Mol. Med. 2009, 9, 255-272.
40. Pagani, M. R.; Reisin, R. C.; Uchitel, O. D. Calcium signaling pathways mediating synaptic potentiation triggered by amyotrophic lateral sclerosis IgG in motor nerve terminals. J. Neurosci. 2006, 26, 2661-2672.
41. 2+ channels. Annu. Rev. Cell Dev. Biol. 2000, 16, 521-555. (Pubitemid 32037516)
42. Schurr, A. Neuroprotection against ischemic/hypoxic brain damage: Blockers of ionotropic glutamate receptor and voltage sensitive calcium channels. Curr. Drug Targets 2004, 5, 603-618. (Pubitemid 39242869)
43. Adams, P. J.; Snutch, T. P. Calcium channelopathies: Voltage-gated calcium channels. Subcell Biochem. 2007, 45, 215-251.
44. Chavis, P.; Fagni, L.; Lansman, J. B.; Bockaert, J. Functional coupling between ryanodine receptors and L-type calcium channels in neurons. Nature 1996, 382, 719-722. (Pubitemid 26282178)
45. Mouton, J.; Marty, I.; Villaz, M.; Feltz, A.; Maulet, Y. Molecular interaction of dihydropyridine receptors with type-1 ryanodine receptors in rat brain. Biochem. J. 2001, 354, 597-603. (Pubitemid 32269723)
46. Krieglstein, J.; Lippert, K.; Poch, G. Apparent independent action of nimodipine and glutamate antagonists to protect cultured neurons against glutamate-induced damage. Neuropharmacology 1996, 35, 1737-1742. (Pubitemid 27090792)
47. Small, D. L.; Monette, R.; Buchan, A. M.; Morley, P. Identification of calcium channels involved in neuronal injury in rat hippocampal slices subjected to oxygen and glucose deprivation. Brain Res. 1997, 753, 209-218. (Pubitemid 27151865)
48. Tally, P. W.; Sundt, T. M.; Anderson, R. E. Improvement of cortical perfusion, intracellular pH, and electrocorticography by nimodipine during transient focal cerebral ischemia. Neurosurgery 1989, 24, 80-87.
49. Lazarewicz, J. W.; Pluta, R.; Puka, M.; Salinska, E. Diverse mechanisms of neuronal protection by nimodipine in experimental rabbit brain ischemia. Stroke 1990, 21, IV108-110.
50. Ohta, S.; Smith, M. L.; Siesjo, B. K. The effect of a dihydropyridine calcium antagonist (isradipine) on selective neuronal necrosis. J. Neurol. Sci. 1991, 103, 109-115.
51. 2+ antagonist nimodipine, influence of aging and developmental drug treatment. Neurodegeneration 1995, 4, 307-314.
52. Campbell, C. A.; Mackay, K. B.; Patel, S.; King, P. D.; Stretton, J. L.; Hadingham, S. J.; Hamilton, T. C. Effects of isradipine, an L-type calcium channel blocker on permanent and transient focal cerebral ischemia in spontaneously hypertensive rats. Exp. Neurol. 1997, 148, 45-50. (Pubitemid 127445113)
53. Kittaka, M.; Giannotta, S. L.; Zelman, V.; Correale, J. D.; DeGiorgio, C. M.; Weiss, M. H.; Zlokovic, B. V. Attenuation of brain injury and reduction of neuron-specific enolase by nicardipine in systemic circulation following focal ischemia and reperfusion in a rat model. J. Neurosurg. 1997, 87, 731-737. (Pubitemid 27454592)
54. Zapater, P.; Moreno, J.; Horga, J. F. Neuroprotection by the novel calcium antagonist PCA50938, nimodipine and flunarizine, in gerbil global brain ischemia. Brain Res. 1997, 772, 57-62. (Pubitemid 27501683)
55. Chandra, S.; White, R. F.; Everding, D.; Feuerstein, G. Z.; Coatney, R. W.; Sarkar, S. K.; Barone, F. C. Use of diffusion-weighted MRI and neurological deficit scores to demonstrate beneficial effects of isradipine in a rat model of focal ischemia. Pharmacology 1999, 58, 292-299. (Pubitemid 29206184)
56. Horn, J.; de Haan, R. J.; Vermeulen, M.; Luiten, P. G.; Limburg, M. Nimodipine in animal model experiments of focal cerebral ischemia: A systematic review. Stroke 2001, 32, 2433-2438. (Pubitemid 32954819)
57. Amenta, F.; Tomassoni, D. Treatment with Nicardipine Protects Brain in an Animal Model of Hypertension-Induced Damage. Clin. Exp. Hypertens. 2004, 26, 351-361. (Pubitemid 38691116)
58. Bailey, S. J.; Wood, N. I.; Samson, N. A.; Rothaul, A. L.; Roberts, J. C.; King, P. D.; Hamilton, T. C.; Harrison, D. C.; Hunter, A. J. Failure of isradipine to reduce infarct size in mouse, gerbil, and rat models of cerebral ischemia. Stroke 1995, 26, 2177-2183.
59. Ginsberg, M. D. Neuroprotection for ischemic stroke: Past, present and future. Neuropharmacology 2008, 55, 363-389.
60. Stevens, T. R.; Krueger, S. R.; Fitzsimonds, R. M.; Picciotto, M. R. Neuroprotection by nicotine in mouse primary cortical cultures involves activation of calcineurin and L-type calcium channel inactivation. J. Neurosci. 2003, 23, 10093-10099.
61. Brewer, L. D.; Thibault, V.; Chen, K. C.; Langub, M. C.; Landfield, P. W.; Porter, N. M. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J. Neurosci. 2001, 21, 98-108. (Pubitemid 32098731)
62. Pinheiro, A. C.; da Silva, A. J.; Prado, M. A.; Cordeiro, M. D.; Richardson, M.; Batista, M. C.; de Castro Junior, C. J.; Massensini, A. R.; Guatimosim, C.; Romano-Silva, M. A.; Kushmerick, C.; Gomez, M. V. Phoneutria spider toxins block ischemia-induced glutamate release, neuronal death, and loss of neurotransmission in hippocampus. Hippocampus 2009, 19, 1123-1129.
63. Pinheiro, A. C. N.; Gomez, R. S.; Massensini, A. R.; Cordeiro, M. N.; Richardson, M.; Romano-Silva, M. A.; Prado, M. A. M.; Marco, L. D.; Gomez, M. V. Neuroprotective effect on brain injury by neurotoxins from the spider Phoneutria nigriventer. Neurochem. Int. 2006, 49, 543-547. (Pubitemid 44192597)
64. León, R.; Ríos, C.d.l.; Marco-Contelles, J.; Huertas, O.; Barril, X.; Javier Luque, F.; López, M. G.; García, A. G.; Villarroya, M. New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection properties. Bioorg. Medicinal Chem. 2008, 16, 7759-7769.
65. Arundine, M.; Tymianski, M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 2003, 34, 325-337. (Pubitemid 37021228)
66. Waxman, E. A.; Lynch, D. R. N-methyl-D-aspartate receptor subtypes: Multiple roles in excitotoxicity and neurological disease. Neuroscientist 2005, 11, 37-49.
67. Rao, V. R.; Finkbeiner, S. NMDA and AMPA receptors: Old channels, new tricks. Trends Neurosci. 2007, 30, 284-291. (Pubitemid 46802833)
68. del Cerro, S.; Arai, A.; Kessler, M.; Bahr, B. A.; Vanderklish, P.; Rivera, S.; Lynch, G. Stimulation of NMDA receptors activates calpain in cultured hippocampal slices. Neurosci. Lett. 1994, 167, 149-152. (Pubitemid 24077661)
69. Hartwick, A. T.; Hamilton, C. M.; Baldridge, W. H. Glutamatergic calcium dynamics and deregulation of rat retinal ganglion cells. J. Physiol. 2008, 586, 3425-3446.
70. McKeage, K. Memantine: A review of its use in moderate to severe Alzheimer's disease. CNS Drugs 2009, 23, 881-897.
71. Thomas, S. J.; Grossberg, G. T. Memantine: A review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin. Interv. Aging. 2009, 4, 367-377.
72. Kornau, H. C.; Schenker, L. T.; Kennedy, M. B.; Seeburg, P. H. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science 1995, 269, 1737-1740.
73. Kim, E.; Cho, K. O.; Rothschild, A.; Sheng, M. Heteromultimerization and NMDA receptorclustering activity of Chapsyn-110, a member of the PSD-95 family of proteins. Neuron 1996, 17, 103-113. (Pubitemid 26251595)
74. Niethammer, M.; Kim, E.; Sheng, M. Interaction between the C terminus of NMDA receptor subunits and multiple members of the PSD-95 family of membrane-associated guanylate kinases. J. Neurosci. 1996, 16, 2157-2163. (Pubitemid 26154327)
75. Dong, H.; O'Brien, R. J.; Fung, E. T.; Lanahan, A. A.; Worley, P. F.; Huganir, R. L. GRIP: A synaptic PDZ domain-containing protein that interacts with AMPA receptors. Nature 1997, 386, 279-284. (Pubitemid 27142513)
76. Kneussel, M.; Brandstatter, J. H.; Laube, B.; Stahl, S.; Muller, U.; Betz, H. Loss of postsynaptic GABA (A) receptor clustering in gephyrin-deficient mice. J. Neurosci. 1999, 19, 9289-9297. (Pubitemid 30228082)
77. Xia, J.; Zhang, X.; Staudinger, J.; Huganir, R. L. Clustering of AMPA receptors by the synaptic PDZ domain-containing protein PICK1. Neuron 1999, 22, 179-187. (Pubitemid 29070104)
78. Daw, M. I.; Chittajallu, R.; Bortolotto, Z. A.; Dev, K. K.; Duprat, F.; Henley, J. M.; Collingridge, G. L.; Isaac, J. T. PDZ proteins interacting with C-terminal GluR2/3 are involved in a PKCdependent regulation of AMPA receptors at hippocampal synapses. Neuron 2000, 28, 873-886. (Pubitemid 32038078)
79. Al-Hallaq, R. A.; Yasuda, R. P.; Wolfe, B. B. Enrichment of N-methyl-D-aspartate NR1 splice variants and synaptic proteins in rat postsynaptic densities. J. Neurochem. 2001, 77, 110-119.
80. Hirbec, H.; Francis, J. C.; Lauri, S. E.; Braithwaite, S. P.; Coussen, F.; Mulle, C.; Dev, K. K.; Coutinho, V.; Meyer, G.; Isaac, J. T.; Collingridge, G. L.; Henley, J. M. Rapid and differential regulation of AMPA and kainate receptors at hippocampal mossy fibre synapses by PICK1 and GRIP. Neuron 2003, 37, 625-638. (Pubitemid 36262984)
81. Rumbaugh, G.; Sia, G. M.; Garner, C. C.; Huganir, R. L. Synapse-associated protein-97 isoformspecific regulation of surface AMPA receptors and synaptic function in cultured neurons. J. Neurosci. 2003, 23, 4567-4576. (Pubitemid 36706187)
82. Gardner, S. M.; Takamiya, K.; Xia, J.; Suh, J. G.; Johnson, R.; Yu, S.; Huganir, R. L. Calciumpermeable AMPA receptor plasticity is mediated by subunit-specific interactions with PICK1 and NSF. Neuron 2005, 45, 903-915. (Pubitemid 40395268)
83. Hanley, J. G.; Henley, J. M. PICK1 is a calcium-sensor for NMDA-induced AMPA receptor trafficking. EMBO J. 2005, 24, 3266-3278. (Pubitemid 41348701)
84. 2+ permeability of AMPARs at cerebellar synapses. Nat. Neurosci. 2005, 8, 768-775.
85. Yi, Z.; Petralia, R. S.; Fu, Z.; Swanwick, C. C.; Wang, Y. X.; Prybylowski, K.; Sans, N.; Vicini, S.; Wenthold, R. J. The role of the PDZ protein GIPC in regulating NMDA receptor trafficking. J. Neurosci. 2007, 27, 11663-11675. (Pubitemid 350006895)
86. Kocsis, J. D.; Rand, M. N.; Chen, B.; Waxman, S. G.; Pourcho, R. Kainate elicits elevated nuclear calcium signals in retinal neurons via calcium-induced calcium release. Brain Res. 1993, 616, 273-282. (Pubitemid 23200056)
87. Lazarewicz, J. W.; Rybkowski, W.; Sadowski, M.; Ziembowicz, A.; Alaraj, M.; Wegiel, J.; Wisniewski, H. M. N-methyl-D-aspartate receptor-mediated, calcium-induced calcium release in rat dentate gyrus/CA4 in vivo. J. Neurosci. Res. 1998, 51, 76-84. (Pubitemid 28063150)
88. Emptage, N.; Bliss, T. V.; Fine, A. Single synaptic events evoke NMDA receptor-mediated release of calcium from internal stores in hippocampal dendritic spines. Neuron 1999, 22, 115-124. (Pubitemid 29070098)
89. Yoshimura, H.; Sugai, T.; Onoda, N.; Segami, N.; Kato, N. Age-dependent occurrence of synchronized population oscillation suggestive of a developing functional coupling between NMDA and ryanodine receptors in the neocortex. Brain Res. Dev. Brain. Res. 2002, 136, 63-68. (Pubitemid 34556985)
90. Fukatsu, K.; Bannai, H.; Zhang, S.; Nakamura, H.; Inoue, T.; Mikoshiba, K. Lateral diffusion of inositol 1,4,5-trisphosphate receptor type 1 is regulated by actin filaments and 4.1N in neuronal dendrites. J. Biol. Chem. 2004, 279, 48976-48982. (Pubitemid 39625779)
91. Wang, Y.; Mattson, M. P.; Furukawa, K. Endoplasmic reticulum calcium release is modulated by actin polymerization. J. Neurochem. 2002, 82, 945-952.
92. 2+ signals in pancreatic acinar cells. J. Cell Sci. 2005, 118, 971-980.
93. Bose, D. D.; Thomas, D. W. The actin cytoskeleton differentially regulates NG115-401L cell ryanodine receptor and inositol 1,4,5-trisphosphate receptor induced calcium signaling pathways. Biochem. Biophys. Res. Commun. 2009, 379, 594-599.
94. Allison, D. W.; Gelfand, V. I.; Spector, I.; Craig, A. M. Role of actin in anchoring postsynaptic receptors in cultured hippocampal neurons: Differential attachment of NMDA versus AMPA receptors. J. Neurosci. 1998, 18, 2423-2436.
95. Lei, S.; Czerwinska, E.; Czerwinski, W.; Walsh, M. P.; MacDonald, J. F. Regulation of NMDA receptor activity by F-actin and myosin light chain kinase. J. Neurosci. 2001, 21, 8464-8472.
96. Sattler, R.; Xiong, Z.; Lu, W. Y.; MacDonald, J. F.; Tymianski, M. Distinct roles of synaptic and extrasynaptic NMDA receptors in excitotoxicity. J. Neurosci. 2000, 20, 22-33.
97. Barria, A.; Malinow, R. Subunit-specific NMDA receptor trafficking to synapses. Neuron 2002, 35, 345-353.
98. Snyder, E. M.; Nong, Y.; Almeida, C. G.; Paul, S.; Moran, T.; Choi, E. Y.; Nairn, A. C.; Salter, M. W.; Lombroso, P. J.; Gouras, G. K.; Greengard, P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 2005, 8, 1051-1058.
99. Almeida, C. G.; Tampellini, D.; Takahashi, R. H.; Greengard, P.; Lin, M. T.; Snyder, E. M.; Gouras, G. K. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol. Dis. 2005, 20, 187-198.
100. Beique, J. C.; Lin, D. T.; Kang, M. G.; Aizawa, H.; Takamiya, K.; Huganir, R. L. Synapse-specific regulation of AMPA receptor function by PSD-95. Proc. Natl. Acad. Sci. USA 2006, 103, 19535-19540.
101. Cao, J.; Viholainen, J. I.; Dart, C.; Warwick, H. K.; Leyland, M. L.; Courtney, M. J. The PSD95-nNOS interface: A target for inhibition of excitotoxic p38 stress-activated protein kinase activation and cell death. J. Cell Biol. 2005, 168, 117-126.
102. Sattler, R.; Xiong, Z.; Lu, W. Y.; Hafner, M.; MacDonald, J. F.; Tymianski, M. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 1999, 284, 1845-1848.
103. Shankar, G. M.; Bloodgood, B. L.; Townsend, M.; Walsh, D. M.; Selkoe, D. J.; Sabatini, B. L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 2007, 27, 2866-2875.
104. Hsieh, H.; Boehm, J.; Sato, C.; Iwatsubo, T.; Tomita, T.; Sisodia, S.; Malinow, R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 2006, 52, 831-843.
105. Kamenetz, F.; Tomita, T.; Hsieh, H.; Seabrook, G.; Borchelt, D.; Iwatsubo, T.; Sisodia, S.; Malinow, R. APP processing and synaptic function. Neuron 2003, 37, 925-937.
106. Bell, J. D.; Park, E.; Ai, J.; Baker, A. J. PICK1-mediated GluR2 endocytosis contributes to cellular injury after neuronal trauma. Cell Death Differ. 2009, 16, 1665-1680.
107. Challis, R. A.; Mistry, R.; Gray, D. W.; Nahorski, S. R. Modulation of muscarinic cholinoceptorstimulated inositol 1,4,5-trisphosphate accumulation by N-methyl-D-aspartate in neonatal rat cerebral cortex. Neuropharmacology 1994, 33, 15-25.
108. 2+ oscillation in cultured rat frontal cortical neurons. J. Neural. Transm. 1997, 104, 811-824.
109. Young, K. W.; Garro, M. A.; Challiss, R. A.; Nahorski, S. R. NMDA-receptor regulation of muscarinic-receptor stimulated inositol 1,4,5-trisphosphate production and protein kinase C activation in single cerebellar granule neurons. J. Neurochem. 2004, 89, 1537-1546.
110. Gao, W. J.; Goldman-Rakic, P. S. NMDA receptor-mediated epileptiform persistent activity requires calcium release from intracellular stores in prefrontal neurons. Exp. Neurol. 2006, 197, 495-504.
111. Ferris, C. D.; Huganir, R. L.; Bredt, D. S.; Cameron, A. M.; Snyder, S. H. Inositol trisphosphate receptor: Phosphorylation by protein kinase C and calcium calmodulin-dependent protein kinases in reconstituted lipid vesicles. Proc Natl. Acad. Sci. USA 1991, 88, 2232-2235.
112. Takasago, T.; Imagawa, T.; Furukawa, K.; Ogurusu, T.; Shigekawa, M. Regulation of the cardiac ryanodine receptor by protein kinase-dependent phosphorylation. J. Biochem. 1991, 109, 163-170.
113. Hain, J.; Nath, S.; Mayrleitner, M.; Fleischer, S.; Schindler, H. Phosphorylation modulates the function of the calcium release channel of sarcoplasmic reticulum from skeletal muscle. Biophys. J. 1994, 67, 1823-1833.
114. Sharma, K.; Wang, L.; Zhu, Y.; Bokkala, S.; Joseph, S. K. Transforming growth factor-beta1 inhibits type I inositol 1,4,5-trisphosphate receptor expression and enhances its phosphorylation in mesangial cells. J. Biol. Chem. 1997, 272, 14617-14623.
115. Wojcikiewicz, R. J.; Luo, S. G. Phosphorylation of inositol 1,4,5-trisphosphate receptors by cAMP-dependent protein kinase. Type I, II, and III receptors are differentially susceptible to phosphorylation and are phosphorylated in intact cells. J. Biol. Chem. 1998, 273, 5670-5677.
116. 2+ signals. J. Biol. Chem. 2000, 275, 33704-33711.
117. Vermassen, E.; Fissore, R. A.; Nadif Kasri, N.; Vanderheyden, V.; Callewaert, G.; Missiaen, L.; Parys, J. B.; De Smedt, H. Regulation of the phosphorylation of the inositol 1,4,5-trisphosphate receptor by protein kinase C. Biochem. Biophys. Res. Commun. 2004, 319, 888-893. (Pubitemid 38739404)
118. 2+/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ. Res. 2004, 94, e61-e70.
119. Bai, G. R.; Yang, L. H.; Huang, X. Y.; Sun, F. Z. Inositol 1,4,5-trisphosphate receptor type 1 phosphorylation and regulation by extracellular signal-regulated kinase. Biochem. Biophys. Res. Commun. 2006, 348, 1319-1327. (Pubitemid 44291346)
120. Khan, M. T.; Wagner, L., 2nd; Yule, D. I.; Bhanumathy, C.; Joseph, S. K. Akt kinase phosphorylation of inositol 1,4,5-trisphosphate receptors. J. Biol. Chem. 2006, 281, 3731-3737. (Pubitemid 43845991)
121. Yang, L. H.; Bai, G. R.; Huang, X. Y.; Sun, F. Z. ERK binds, phosphorylates InsP3 type 1 receptor and regulates intracellular calcium dynamics in DT40 cells. Biochem. Biophys. Res. Commun. 2006, 349, 1339-1344.
122. 2+in pancreatoma AR4-2J cells. J. Endocrinol. 2007, 192, 659-668. (Pubitemid 46455968)
123. Caron, A. Z.; Chaloux, B.; Arguin, G.; Guillemette, G. Protein kinase C decreases the apparent affinity of the inositol 1,4,5-trisphosphate receptor type 3 in RINm5F cells. Cell Calcium. 2007, 42, 323-331. (Pubitemid 47074403)
124. Koulen, P.; Madry, C.; Duncan, R. S.; Hwang, J. Y.; Nixon, E.; McClung, N.; Gregg, E. V.; Singh, M. Progesterone potentiates IP (3) -mediated calcium signaling through Akt/PKB. Cell Physiol. Biochem. 2008, 21, 161-172.
125. Hwang, J. Y.; Duncan, R. S.; Madry, C.; Singh, M.; Koulen, P. Progesterone potentiates calcium release through IP3 receptors by an Akt-mediated mechanism in hippocampal neurons. Cell Calcium 2009, 45, 233-242.
126. Xiao, B.; Tu, J. C.; Petralia, R. S.; Yuan, J. P.; Doan, A.; Breder, C. D.; Ruggiero, A.; Lanahan, A. A.; Wenthold, R. J.; Worley, P. F. Homer regulates the association of group 1 metabotropic glutamate receptors with multivalent complexes of homer-related, synaptic proteins. Neuron 1998, 21, 707-716.
127. Naisbitt, S.; Kim, E.; Tu, J. C.; Xiao, B.; Sala, C.; Valtschanoff, J.; Weinberg, R. J.; Worley, P. F.; Sheng, M. Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin. Neuron 1999, 23, 569-582.
128. Tu, J. C.; Xiao, B.; Naisbitt, S.; Yuan, J. P.; Petralia, R. S.; Brakeman, P.; Doan, A.; Aakalu, V. K.; Lanahan, A. A.; Sheng, M.; Worley, P. F. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 1999, 23, 583-592.
129. Sala, C.; Piech, V.; Wilson, N. R.; Passafaro, M.; Liu, G.; Sheng, M. Regulation of dendritic spine morphology and synaptic function by Shank and Homer. Neuron 2001, 31, 115-130. (Pubitemid 32757093)
130. Gilman, A. G. G proteins: Transducers of receptor-generated signals. Annu. Rev. Biochem. 1987, 56, 615-649.
131. Simon, M. I.; Strathmann, M. P.; Gautam, N. Diversity of G proteins in signal transduction. Science 1991, 252, 802-808.
132. Rosenbaum, D. M.; Rasmussen, S. G.; Kobilka, B. K. The structure and function of G-proteincoupled receptors. Nature 2009, 459, 356-363.
133. Oldham, W. M.; Hamm, H. E. Heterotrimeric G protein activation by G-protein-coupled receptors. Nat. Rev. Mol. Cell Biol. 2008, 9, 60-71.
134. Johnston, C. A.; Siderovski, D. P. Siderovski, Receptor-mediated activation of heterotrimeric Gproteins: Current structural insights. Mol. Pharmacol. 2007, 72, 219-230.
135. Mizuno, N.; Itoh, H. Functions and Regulatory Mechanisms of Gq-Signaling Pathways. Neurosignals 2009, 17, 42-54.
136. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258, 1946-1949.
137. Mechoulam, R.; Ben-Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N. E.; Schatz, A. R.; Gopher, A.; Almog, S.; Martin, B. R.; Compton, D. R.; Pertwee, R. G.; Griffin, G.; Bayewitch, M.; Barg, J.; Vogel, Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 1995, 50, 83-90.
138. Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamashita, A.; Waku, K. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 1995, 215, 89-97.
139. Gomes, I.; Grushko, J. S.; Golebiewska, U.; Hoogendoorn, S.; Gupta, A.; Heimann, A. S.; Ferro, E. S.; Scarlata, S.; Fricker, L. D.; Devi, L. A. Novel endogenous peptide agonists of cannabinoid receptors. FASEB J. 2009, 23, 3020-3029.
140. Howlett, A. C.; Fleming, R. M. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol. Pharmacol. 1984, 26, 532-538.
141. Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 2002, 54, 161-202. (Pubitemid 34575709)
142. Twitchell, W.; Brown, S.; Mackie, K. Cannabinoids inhibit N-and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol. 1997, 78, 43-50. (Pubitemid 27318909)
143. Mackie, K.; Hille, B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA 1992, 89, 3825-3829.
144. Felder, C. C.; Briley, E. M.; Axelrod, J.; Simpson, J. T.; Mackie, K.; Devane, W. A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA 1993, 90, 7656-7660.
145. Lalonde, M. R.; Jollimore, C. A.; Stevens, K.; Barnes, S.; Kelly, M. E. Cannabinoid receptormediated inhibition of calcium signaling in rat retinal ganglion cells. Mol. Vis. 2006, 12, 1160-1166. (Pubitemid 44538153)
146. Lauckner, J. E.; Hille, B.; Mackie, K. The cannabinoid agonist WIN55, 212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc. Natl. Acad. Sci. USA 2005, 102, 19144-19149.
147. Abood, M. E.; Rizvi, G.; Sallapudi, N.; McAllister, S. D. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci. Lett. 2001, 309, 197-201. (Pubitemid 32763173)
148. Gilbert, G. L.; Kim, H. J.; Waataja, J. J.; Thayer, S. A. Thayer, Delta9-tetrahydrocannabinol protects hippocampal neurons from excitotoxicity. Brain Res. 2007, 1128, 61-69.
149. Hampson, A. J.; Bornheim, L. M.; Scanziani, M.; Yost, C. S.; Gray, A. T.; Hansen, B. M.; Leonoudakis, D. J.; Bickler, P. E. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J. Neurochem. 1998, 70, 671-676. (Pubitemid 28079356)
150. Shen, M.; Thayer, S. A. Thayer, Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. 1998, 54, 459-462. (Pubitemid 28442938)
151. Liu, Q.; Bhat, M.; Bowen, W. D.; Cheng, J. Signaling pathways from CB1 receptor activation to inhibition of NMDA-mediated calcium influx and neurotoxicity in dorsal root ganglion neurons. J. Pharmacol. Exp. Ther. 2009, 331, 1062-1070.
152. Shen, M.; Piser, T. M.; Seybold, V. S.; Thayer, S. A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 1996, 16, 4322-4334. (Pubitemid 26243028)
153. Kim, S. H.; Won, S. J.; Mao, X. O.; Jin, K.; Greenberg, D. A. Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity. Mol. Pharmacol. 2006, 69, 691-696. (Pubitemid 43363843)
154. Zhuang, S. Y.; Bridges, D.; Grigorenko, E.; McCloud, S.; Boon, A.; Hampson, R. E.; Deadwyler, S. A. Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores. Neuropharmacology 2005, 48, 1086-1096. (Pubitemid 40725981)
155. Flammer, J.; Orgul, S.; Costa, V. P.; Orzalesi, N.; Krieglstein, G. K.; Serra, L. M.; Renard, J. P.; Stefansson, E. The impact of ocular blood flow in glaucoma. Prog. Retin. Eye Res. 2002, 21, 359-393.
156. Galanopoulos, A.; Goldberg, I. Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension. Clin. Ophthalmol. 2009, 3, 117-122.
157. Donello, J. E.; Padillo, E. U.; Webster, M. L.; Wheeler, L. A.; Gil, D. W. alpha (2) -Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J. Pharmacol. Exp. Ther. 2001, 296, 216-223.
158. Baptiste, D. C.; Hartwick, A. T.; Jollimore, C. A.; Baldridge, W. H.; Chauhan, B. C.; Tremblay, F.; Kelly, M. E. Comparison of the neuroprotective effects of adrenoceptor drugs in retinal cell culture and intact retina. Invest. Ophthalmol. Vis. Sci. 2002, 43, 2666-2676.
159. Grunert, U.; Haverkamp, S.; Fletcher, E. L.; Wassle, H. Synaptic distribution of ionotropic glutamate receptors in the inner plexiform layer of the primate retina. J. Comp. Neurol. 2002, 447, 138-151. (Pubitemid 34457375)
160. Sun, D.; Rait, J. L.; Kalloniatis, M. Inner retinal neurons display differential responses to Nmethyl-D-aspartate receptor activation. J. Comp. Neurol. 2003, 465, 38-56. (Pubitemid 37075679)
161. Dreyer, E. B.; Zurakowski, D.; Schumer, R. A.; Podos, S. M.; Lipton, S. A. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Ophthalmol. 1996, 114, 299-305.
162. Louzada-Junior, P.; Dias, J. J.; Santos, W. F.; Lachat, J. J.; Bradford, H. F.; Coutinho-Netto, J. Glutamate release in experimental ischaemia of the retina: An approach using microdialysis. J. Neurochem. 1992, 59, 358-363.
163. Neal, M. J.; Cunningham, J. R.; Hutson, P. H.; Hogg, J. Effects of ischaemia on neurotransmitter release from the isolated retina. J. Neurochem. 1994, 62, 1025-1033.
164. Perlman, J. I.; McCole, S. M.; Pulluru, P.; Chang, C. J.; Lam, T. T.; Tso, M. O. Disturbances in the distribution of neurotransmitters in the rat retina after ischemia. Curr. Eye Res. 1996, 15, 589-596.
165. Chizh, B. A. Low dose ketamine: A therapeutic and research tool to explore N-methyl-Daspartate (NMDA) receptor-mediated plasticity in pain pathways. J. Psychopharmacol. 2007, 21, 259-271.
166. Pittenger, C.; Sanacora, G.; Krystal, J. H. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol. Disord. Drug Targets 2007, 6, 101-115.
167. Hare, W.; WoldeMussie, E.; Lai, R.; Ton, H.; Ruiz, G.; Feldmann, B.; Wijono, M.; Chun, T.; Wheeler, L. Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey. Surv. Ophthalmol. 2001, 45 (Suppl. 3), S284-S289; discussion S285-S286.
168. Lagreze, W. A.; Knorle, R.; Bach, M.; Feuerstein, T. J. Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. Invest. Ophthalmol. Vis. Sci. 1998, 39, 1063-1066.
169. Osborne, N. N. Memantine reduces alterations to the mammalian retina, in situ, induced by ischemia. Vis. Neurosci. 1999, 16, 45-52.
170. WoldeMussie, E.; Yoles, E.; Schwartz, M.; Ruiz, G.; Wheeler, L. A. Neuroprotective effect of memantine in different retinal injury models in rats. J. Glaucoma 2002, 11, 474-480.
171. Hare, W. A.; WoldeMussie, E.; Lai, R. K.; Ton, H.; Ruiz, G.; Chun, T.; Wheeler, L. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. Invest. Ophthalmol. Vis. Sci. 2004, 45, 2625-2639. (Pubitemid 38998859)
172. Hare, W. A.; WoldeMussie, E.; Weinreb, R. N.; Ton, H.; Ruiz, G.; Wijono, M.; Feldmann, B.; Zangwill, L.; Wheeler, L. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. Invest. Ophthalmol. Vis. Sci. 2004, 45, 2640-2651. (Pubitemid 38998860)
173. WoldeMussie, E.; Ruiz, G.; Wijono, M.; Wheeler, L. A. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest. Ophthalmol. Vis. Sci. 2001, 42, 2849-2855.
174. Kalapesi, F. B.; Coroneo, M. T.; Hill, M. A. Human ganglion cells express the alpha-2 adrenergic receptor: Relevance to neuroprotection. Br. J. Ophthalmol. 2005, 89, 758-763.
175. Katz, L. J.; Simmons, S. T.; Craven, E. R. Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension. Curr. Med. Res. Opin. 2007, 23, 2971-2983.
176. Dong, C. J.; Guo, Y.; Wheeler, L.; Hare, W. A. Alpha2 adrenergic receptor-mediated modulation of cytosolic Ca++ signals at the inner plexiform layer of the rat retina. Invest. Ophthalmol. Vis. Sci. 2007, 48, 1410-1415.
177. Lakhlani, P. P.; Lovinger, D. M.; Limbird, L. E. Genetic evidence for involvement of multiple effector systems in alpha 2A-adrenergic receptor inhibition of stimulus-secretion coupling. Mol. Pharmacol. 1996, 50, 96-103.
178. Dong, C. J.; Guo, Y.; Agey, P.; Wheeler, L.; Hare, W. A. Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest. Ophthalmol. Vis. Sci. 2008, 49, 4515-4522.
179. 2+ channels in rat sympathetic neurones. J. Physiol. 1999, 518, 23-36.
180. Cowburn, R. F.; Popescu, B. O.; Ankarcrona, M.; Dehvari, N.; Cedazo-Minguez, A. Presenilinmediated signal transduction. Physiol. Behav. 2007, 92, 93-97.
181. Lah, J. J.; Heilman, C. J.; Nash, N. R.; Rees, H. D.; Yi, H.; Counts, S. E.; Levey, A. I. Light and electron microscopic localization of presenilin-1 in primate brain. J. Neurosci. 1997, 17, 1971-1980. (Pubitemid 27106756)
182. Lee, M. K.; Slunt, H. H.; Martin, L. J.; Thinakaran, G.; Kim, G.; Gandy, S. E.; Seeger, M.; Koo, E.; Price, D. L.; Sisodia, S. S. Expression of presenilin 1 and 2 (PS1 and PS2) in human and murine tissues. J. Neurosci. 1996, 16, 7513-7525. (Pubitemid 26389690)
183. Levey, A. I.; Heilman, C. J.; Lah, J. J.; Nash, N. R.; Rees, H. D.; Wakai, M.; Mirra, S. S.; Rye, D. B.; Nochlin, D.; Bird, T. D.; Mufson, E. J. Presenilin-1 protein expression in familial and sporadic Alzheimer's disease. Ann. Neurol. 1997, 41, 742-753. (Pubitemid 27249179)
184. Nakajima, M.; Moriizumi, E.; Koseki, H.; Shirasawa, T. Presenilin 1 is essential for cardiac morphogenesis. Dev. Dyn. 2004, 230, 795-799. (Pubitemid 38993879)
185. Shen, J.; Bronson, R. T.; Chen, D. F.; Xia, W.; Selkoe, D. J.; Tonegawa, S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell 1997, 89, 629-639. (Pubitemid 27511773)
186. Donoviel, D. B.; Hadjantonakis, A. K.; Ikeda, M.; Zheng, H.; Hyslop, P. S.; Bernstein, A. Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes. Dev. 1999, 13, 2801-2810.
187. Borchelt, D. R.; Thinakaran, G.; Eckman, C. B.; Lee, M. K.; Davenport, F.; Ratovitsky, T.; Prada, C. M.; Kim, G.; Seekins, S.; Yager, D.; Slunt, H. H.; Wang, R.; Seeger, M.; Levey, A. I.; Gandy, S. E.; Copeland, N. G.; Jenkins, N. A.; Price, D. L.; Younkin, S. G.; Sisodia, S. S. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996, 17, 1005-1013. (Pubitemid 26424026)
188. Cedazo-Minguez, A.; Popescu, B. O.; Ankarcrona, M.; Nishimura, T.; Cowburn, R. F. The presenilin 1 deltaE9 mutation gives enhanced basal phospholipase C activity and a resultant increase in intracellular calcium concentrations. J. Biol. Chem. 2002, 277, 36646-36655.
189. Chyung, J. H.; Raper, D. M.; Selkoe, D. J. Gamma-secretase exists on the plasma membrane as an intact complex that accepts substrates and effects intramembrane cleavage. J. Biol. Chem. 2005, 280, 4383-4392.
190. Lee, M. K.; Borchelt, D. R.; Kim, G.; Thinakaran, G.; Slunt, H. H.; Ratovitski, T.; Martin, L. J.; Kittur, A.; Gandy, S.; Levey, A. I.; Jenkins, N.; Copeland, N.; Price, D. L.; Sisodia, S. S. Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nat. Med. 1997, 3, 756-760. (Pubitemid 27298719)
191. Green, K. N.; LaFerla, F. M. Linking calcium to Abeta and Alzheimer's disease. Neuron 2008, 59, 190-194.
192. Laudon, H.; Hansson, E. M.; Melen, K.; Bergman, A.; Farmery, M. R.; Winblad, B.; Lendahl, U.; von Heijne, G.; Naslund, J. A nine-transmembrane domain topology for presenilin 1. J. Biol. Chem. 2005, 280, 35352-35360. (Pubitemid 41532724)
193. Thinakaran, G.; Borchelt, D. R.; Lee, M. K.; Slunt, H. H.; Spitzer, L.; Kim, G.; Ratovitsky, T.; Davenport, F.; Nordstedt, C.; Seeger, M.; Hardy, J.; Levey, A. I.; Gandy, S. E.; Jenkins, N. A.; Copeland, N. G.; Price, D. L.; Sisodia, S. S. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 1996, 17, 181-190. (Pubitemid 26251602)
194. Spasic, D.; Tolia, A.; Dillen, K.; Baert, V.; De Strooper, B.; Vrijens, S.; Annaert, W. Presenilin-1 maintains a nine-transmembrane topology throughout the secretory pathway. J. Biol. Chem. 2006, 281, 26569-26577.
195. Capell, A.; Grunberg, J.; Pesold, B.; Diehlmann, A.; Citron, M.; Nixon, R.; Beyreuther, K.; Selkoe, D. J.; Haass, C. The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100-150-kDa molecular mass complex. J. Biol. Chem. 1998, 273, 3205-3211.
196. Ribaut-Barassin, C.; Dupont, J. L.; Haeberle, A. M.; Bombarde, G.; Huber, G.; Moussaoui, S.; Mariani, J.; Bailly, Y. Alzheimer's disease proteins in cerebellar and hippocampal synapses during postnatal development and aging of the rat. Neuroscience 2003, 120, 405-423.
197. Leissring, M. A.; Akbari, Y.; Fanger, C. M.; Cahalan, M. D.; Mattson, M. P.; LaFerla, F. M. Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. J. Cell. Biol. 2000, 149, 793-798.
198. Leissring, M. A.; LaFerla, F. M.; Callamaras, N.; Parker, I. Subcellular mechanisms of presenilinmediated enhancement of calcium signaling. Neurobiol. Dis. 2001, 8, 469-478.
199. Leissring, M. A.; Yamasaki, T. R.; Wasco, W.; Buxbaum, J. D.; Parker, I.; LaFerla, F. M. Calsenilin reverses presenilin-mediated enhancement of calcium signaling. Proc. Natl. Acad. Sci. USA 2000, 97, 8590-8593.
200. Mattson, M. P.; Zhu, H.; Yu, J.; Kindy, M. S. Presenilin-1 mutation increases neuronal vulnerability to focal ischemia in vivo and to hypoxia and glucose deprivation in cell culture: Involvement of perturbed calcium homeostasis. J. Neurosci. 2000, 20, 1358-1364.
201. 2+ leak function of presenilin 1. J. Clin. Invest. 2007, 117, 1230-1239.
202. Smith, I. F.; Green, K. N.; LaFerla, F. M. Calcium dysregulation in Alzheimer's disease: Recent advances gained from genetically modified animals. Cell Calcium 2005, 38, 427-437.
203. 2+ signaling. FASEB J. 2005, 19, 2069-2071. (Pubitemid 41759768)
204. Zatti, G.; Burgo, A.; Giacomello, M.; Barbiero, L.; Ghidoni, R.; Sinigaglia, G.; Florean, C.; Bagnoli, S.; Binetti, G.; Sorbi, S.; Pizzo, P.; Fasolato, C. Presenilin mutations linked to familial Alzheimer's disease reduce endoplasmic reticulum and Golgi apparatus calcium levels. Cell Calcium 2006, 39, 539-550.
205. 2+ release from intracellular stores. Neurobiol. Dis. 2004, 15, 269-278. (Pubitemid 38296758)
206. Reddy, P. H.; McWeeney, S. Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models. Neurobiol. Aging 2006, 27, 1060-1077. (Pubitemid 43850649)
207. Khachaturian, Z. S. Hypothesis on the regulation of cytosol calcium concentration and the aging brain. Neurobiol. Aging 1987, 8, 345-346.
208. Mattson, M. P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430, 631-639.
209. Li, D.; Parks, S. B.; Kushner, J. D.; Nauman, D.; Burgess, D.; Ludwigsen, S.; Partain, J.; Nixon, R. R.; Allen, C. N.; Irwin, R. P.; Jakobs, P. M.; Litt, M.; Hershberger, R. E. Mutations of presenilin genes in dilated cardiomyopathy and heart failure. Am. J. Hum. Genet. 2006, 79, 1030-1039.
210. Lee, J. A.; Allen, D. G. Changes in intracellular free calcium concentration during long exposures to simulated ischemia in isolated mammalian ventricular muscle. Circ. Res. 1992, 71, 58-69.
211. Murphy, E.; Steenbergen, C. Mechanisms underlying acute protection from cardiac ischemiareperfusion injury. Physiol. Rev. 2008, 88, 581-609.
212. Vinten-Johansen, J.; Jiang, R.; Reeves, J. G.; Mykytenko, J.; Deneve, J.; Jobe, L. J. Inflammation, proinflammatory mediators and myocardial ischemia-reperfusion Injury. Hematol. Oncol. Clin. North Am. 2007, 21, 123-145. (Pubitemid 46156986)
213. Mohuczy, D.; Qian, K.; Phillips, M. I. Presenilins in the heart: Presenilin-2 expression is increased by low glucose and by hypoxia in cardiac cells. Regul. Pept. 2002, 110, 1-7. (Pubitemid 35439144)
214. 2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Cell 2006, 126, 981-993. (Pubitemid 44310781)
215. Pack-Chung, E.; Meyers, M. B.; Pettingell, W. P.; Moir, R. D.; Brownawell, A. M.; Cheng, I.; Tanzi, R. E.; Kim, T. W. Presenilin 2 interacts with sorcin, a modulator of the ryanodine receptor. J. Biol. Chem. 2000, 275, 14440-14445. (Pubitemid 30339730)
216. Meyers, M. B.; Pickel, V. M.; Sheu, S. S.; Sharma, V. K.; Scotto, K. W.; Fishman, G. I. Association of sorcin with the cardiac ryanodine receptor. J. Biol. Chem. 1995, 270, 26411-26418.
217. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 1985, 260, 3440-3450.
218. Subach, F. V.; Patterson, G. H.; Manley, S.; Gillette, J. M.; Lippincott-Schwartz, J.; Verkhusha, V. V. Photoactivatable mCherry for high-resolution two-color fluorescence microscopy. Nat. Meth. 2009, 6, 153-159.
219. Gupta, S.; Singh, R. K.; Nanda, K.; Chatterjee, M.; Tiwari, A.; Sundaram, S.; Gupta, D.; Chugh, A.; Dastidar, S.; Ray, A. Ratiometric Ca+2 measurement in human recombinant muscarinic receptor subtypes using the Flexstation scanning fluorometer. J. Recept. Signal. Transduct. Res. 2009, 29, 100-106.
220. 2+ indicator-caused fluorescence artifact. Anal. Biochem. 2009, 390, 212-214.
221. Heisenberg, W. Über den anschaulichen Inhalt der quantentheoretischen Kinematik und Mechanik. Z. Phys. A-Hadron. Nucl. 1927, 43, 172-198.
222. Mank, M.; Griesbeck, O. Genetically encoded calcium indicators. Chem. Rev 2008, 108, 1550-1564.
223. Tian, L.; Hires, S. A.; Mao, T.; Huber, D.; Chiappe, M. E.; Chalasani, S. H.; Petreanu, L.; Akerboom, J.; McKinney, S. A.; Schreiter, E. R.; Bargmann, C. I.; Jayaraman, V.; Svoboda, K.; Looger, L. L. Imaging neural activity in worms, flies and mice with improved GCaMP calcium indicators. Nat. Methods 2009, 6, 875-881.
224. Hell, S. W. Far-field optical nanoscopy. Science 2007, 316, 1153-1158.
225. Hell, S. W. Toward fluorescence nanoscopy. Nat. Biotechnol. 2003, 21, 1347-1355.
226. Pawley, J. B. Handbook of Biological Confocal Microscopy, 3rd ed.; Springer: New York, USA, 2006; pp: 985.
227. Huang, B.; Bates, M.; Zhuang, X. Super-resolution fluorescence microscopy. Annu. Rev. Biochem. 2009, 78, 993-1016.
228. Hell, S. W.; Wichmann, J. Breaking the diffraction resolution limit by stimulated emission: Stimulated-emission-depletion fluorescence microscopy. Opt. Lett. 1994, 19, 780-782.
229. Klar, T. A.; Hell, S. W. Subdiffraction resolution in far-field fluorescence microscopy. Opt. Lett. 1999, 24, 954-956.
230. Hess, S. T.; Girirajan, T. P.; Mason, M. D. Ultra-high resolution imaging by fluorescence photoactivation localization microscopy. Biophys. J. 2006, 91, 4258-4272.
231. Betzig, E.; Patterson, G. H.; Sougrat, R.; Lindwasser, O. W.; Olenych, S.; Bonifacino, J. S.; Davidson, M. W.; Lippincott-Schwartz, J.; Hess, H. F. Imaging intracellular fluorescent proteins at nanometer resolution. Science 2006, 313, 1642-1645.
232. Neil, M. A. A.; Juskaitis, R.; Wilson, T. Method of obtaining optical sectioning by using structured light in a conventional microscope. Opt. Lett. 1997, 22, 1905-1907.
233. Gustafsson, M. G. Nonlinear structured-illumination microscopy: Wide-field fluorescence imaging with theoretically unlimited resolution. Proc. Natl. Acad. Sci. USA 2005, 102, 13081-13086.
234. Begley, R. F.; Harvey, A. B.; Byer, R. L. Coherent anti-Stokes Raman spectoscopy. Appl. Phys. Lett. 1974, 25, 387-390.
235. Hell, S. W.; Stelzer, E. H.; Lindek, S.; Confocal microscopy with an increased detection aperture: Type-B 4pi confocal microscopy. Opt. Lett. 1994, 19, 222.
236. Rust, M. J.; Bates, M.; Zhuang, X. Sub-diffraction-limit imaging by stochastic optical reconstruction microscopy (STORM). Nat. Methods 2006, 3, 793-795.
237. 2+ signals and neuronal death in brain ischemia. Stroke 2007, 38, 674-676.
238. Bezprozvanny, I. Calcium signaling and neurodegenerative diseases. Trends Mol. Med. 2009, 15, 89-100.